Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.60 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.56 |
| ▸ | HTR3B | O95264 | 3/20 | 0.56 |
| ▸ | HTR3A | P46098 | 3/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2869885 | 0.98 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR7ADRB1HTR3E | |
| Tert-Butyl Formate SCHEMBL28258175 | 0.87 | CHRNB2 (0.48) | CHRNB2CHRNA4HTR7ADRB1HTR3E | |
| SCHEMBL361649 | 0.85 | ADRB1 (0.61) | CHRNB2CHRNA4HTR7ADRB1HTR3E | |
| SCHEMBL23705839 | 0.85 | ALDH1A1 (0.55) | CHRNB2CHRNA4LMNAMAPT | |
| SCHEMBL31091978 | 0.85 | ALDH1A1 (0.55) | CHRNB2CHRNA4LMNAMAPT | |
| Hydrochloric Acid SCHEMBL7711565 | 0.83 | ADRB1 (0.59) | CHRNB2CHRNA4HTR7ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL2156292 | 0.83 | ADRB1 (0.59) | CHRNB2CHRNA4HTR7ADRB1HTR3E | |
| SCHEMBL807418 | 0.83 | ALDH1A1 (0.58) | LMNAMAPT | |
| SCHEMBL2384047 | 0.82 | SIRT6 (0.58) | HTR3AACVR1DRD2DRD3HTR6 | |
| SCHEMBL10154835 | 0.82 | ADRB1 (0.57) | CHRNB2CHRNA4HTR7ADRB1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2968316-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1366030-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | Neurogen Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2002004433-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CHRNB2 3004/4885CHRNA4 3264/4885HTR7 3267/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2154/4885CHRNA4 1666/4885HTR7 3334/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CHRNB2 2368/4885CHRNA4 2252/4885HTR7 559/4885 |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FASN, IL1RN, CCR1 | CHRNB2 4314/4885CHRNA4 4513/4885HTR7 3850/4885 |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | CHRNB2 402/4885CHRNA4 408/4885HTR7 119/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | CHRNB2 383/4885CHRNA4 391/4885HTR7 112/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRNB2 2154/4885CHRNA4 1666/4885HTR7 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.